Research programme: cystic fibrosis therapy - Inologic
Alternative Names: Cystic fibrosis therapy research programme - Inologic; INO 4995Latest Information Update: 16 Jul 2016
At a glance
- Originator Inologic
- Class Inositol phosphates
- Mechanism of Action Ion channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cystic fibrosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cystic-fibrosis in USA
- 03 Dec 2003 INO 4995 has received orphan drug status for cystic fibrosis in USA
- 20 Oct 2003 Inologic has selected a lead compound, INO 4995, for clinical development